BioPharma Business Case & Opportunity Assessments
Case 1: Commercial Opportunity Assessment for Pipeline Products​
Situation
-
A top 5 pharmaceutical company needed to prioritize pipeline candidates and acquisition targets in rheumatoid arthritis.
-
Leadership was uncertain which compounds had the strongest commercial viability.
Action
-
Conducted a comprehensive assessment by mapping patient flow, estimating market size, and evaluating the commercial value of clinical trial endpoints.
-
Gauged potential payer interest by analyzing reimbursement trends and insurance dynamics.
Result
-
Provided a synthesized recommendation that enabled the client to prioritize high-value opportunities, supporting strategic investment decisions in multi-billion-dollar therapeutic markets.
Case 2: Indication Prioritization for Pipeline Compound
Situation
-
One of the top 5 largest pharmaceutical companies had a chemical compound in development with promise across multiple potential indications.
-
Funding was not available to equally devote development across all indications, so a decision had to be made for which indication to prioritize.
-
The client faced uncertainty about which therapeutic indication would yield the strongest commercial return.
Action
-
Evaluated multiple potential indications through a comprehensive competitive landscape analysis.
-
Included analysis on willingness to pay by payers, and unmet need assessment according to both physicians and patients.
Result
-
Measured the likely market size and penetration across all indications, and compared against launch timelines.
-
Recommended the most commercially attractive indication. Of the remaining possible indications, also prioritized them for future development.
-
End result shaped the client’s development strategy and accelerated investment toward the most profitable path.
Case 3: Aligning R&D Pipeline with U.S. Commercial Input
Situation
-
A top 10 European pharmaceutical client had historically focused on R&D without integrating U.S. commercial perspectives.
-
As a result, trials were often designed with endpoints that lacked U.S. commercial relevance, leading to FDA rejections (e.g., weight-loss drug trials that were categorized as “lifestyle” rather than medical).
Action
-
Helped the client incorporate U.S. commercial insights into global pipeline strategy.
-
Advised on structuring clinical trial endpoints aligned with FDA expectations and payer considerations.
Result
-
Improved trial design and pipeline prioritization, reducing regulatory risk and ensuring alignment with market demand.